title: Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
authors.affiliation: Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
authors.forename: D
authors.initials: D
authors.lastname: Zamarin
authors.forename: S M
authors.initials: SM
authors.lastname: Devlin
authors.forename: M E
authors.initials: ME
authors.lastname: Arcila
authors.forename: H
authors.initials: H
authors.lastname: Landau
authors.forename: A
authors.initials: A
authors.lastname: Lesokhin
authors.forename: N
authors.initials: N
authors.lastname: Lendvai
authors.forename: D J
authors.initials: DJ
authors.lastname: Chung
authors.forename: D
authors.initials: D
authors.lastname: Chimento
authors.forename: J
authors.initials: J
authors.lastname: Weltz
authors.forename: D
authors.initials: D
authors.lastname: Babu
authors.forename: S
authors.initials: S
authors.lastname: Giralt
authors.forename: H
authors.initials: H
authors.lastname: Hassoun
mesh_terms: D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015994:Incidence; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D011379:Prognosis; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide